One World. One Standard. ® Epilepsy is a global problem that deserves a global solution.™

Featured Updates

July 15, 2020

COVID-19 and Epilepsy

COVID-19 is impacting our world in dramatic and deadly ways, and those with medical conditions like epilepsy who live in under-resourced areas are among the hardest hit. These are some of the challenges our partners are reporting...
June 17, 2020

A Look Back at ROW’s First Partnership

This month marks the fifth anniversary of the ROW Foundation’s first grant. On June 17, 2015 we granted an EEG machine (used to diagnosis epilepsy) to the Armenian League Against Epilepsy (ALAE) for use at the Arabkir Pediatric Hospital in Yerevan, Armenia. This machine was a major step forward for the hospital being able to...
May 26, 2020

Addressing the Treatment Gap in the DRC

Because poverty and the epilepsy treatment gap go hand-in-hand, the ROW Foundation was delighted when Dr. Prince Kazadi reached out to us regarding a partnership in the Democratic Republic of the Congo (DRC). The DRC is often called “the poorest rich country in the world” because of its rich resources coupled with...
April 14, 2020

Reducing Risk in Trying Times

We hope you are all staying safe in the midst of the global challenges of the Coronvirus pandemic. Its’ impact is being felt in every country, including those where our partners work. A recent email from Dr. Archana Patel of Boston Children’s Hospital, who is the Project Lead for our Community Health Worker (CHW) partnership...
doc-icon

The Challenge

The vast majority of people living with epilepsy and associated psychiatric disorders in the developed world have their disorders controlled, typically with medication. But patients in the rest of the world go without these diagnostic tools, effective treatments and basic medications.

money-icon

The Process

The ROW Foundation is pursuing change. The ROW Foundation is a shareholder of OWP Pharmaceuticals, a for-profit company that produces neurology and psychiatry medications. Profits from OWP fund the charitable projects of ROW. Working together, the two organizations are an expression of sustainable philanthropy that can change the world.

kit-icon

The Solution

The ROW Foundation provides treatment resources, including Roweepra® and Subvenite®, to people with epilepsy and associated psychiatric disorders. ROW also helps neurologists and psychiatrists in the developed world train practitioners in the developing world to more effectively treat epilepsy and associated psychiatric disorders.

We share the World Health Organization's belief that, “the highest attainable standard of health as a fundamental right of every human being.” In that spirit, we're working toward a world in which the same standard of care for epilepsy and associated psychiatric disorders is available to all people, at all times, in all the world.

Vision

The ROW Foundation exists to improve the lives of people living with epilepsy and associated psychiatric disorders in under-resourced areas of the world. We envision a future when the best treatments will be available to all people, at all times, in all the world.

Mission

In fulfilling our vision, the ROW Foundation works to improve the quality of training, diagnosis and treatment available to people with epilepsy and associated psychiatric disorders in under-resourced areas of the world. We partner with other organizations to maximize impact in under-served areas, both domestically and internationally.

row-vision-mission

Subscribe to Receive Monthly Updates

Receive a free e-version of our book, One World One Standard

Subscribe to Receive Monthly Updates

Receive a free e-version of our book, One World One Standard

One World. One Standard.®

The map shows our completed, ongoing and future projects. Click on highlighted countries to see what we’re doing around the world.

Completed Projects
Ongoing Projects
Multiple Projects

Diagnosis and Treatment Grants (Multiple)

In 2015, a diagnosis grant in the form of a 32-channel video EEG workstation was given to the Armenia League Against Epilepsy, to be placed at Arabkir Pediatric Hospital in the capital city of Yerevan. Beginning in October 2016, an ongoing treatment grant has supplied the hospital with Roweepra® (levetiracetam USP) anti-seizure medication. In 2019, the grant was expanded to add an ongoing supply of Subvenite® (lamotrigine USP) anti-seizure medication.

Treatment Grant (Ongoing)

In 2019, a treatment grant was provided to Armenia Artsakh Fund. This grant provides Subvenite® (lamotrigine USP) to the Karabagh Ministry of Health.

Treatment Grant (Ongoing)

In 2018, a treatment grant of Roweepra® (levetiracetam USP) was provided to Solidarity Bridge/Puente Solidaridad for use in the nation’s first comprehensive epilepsy center at Belga Hospital in Cochabamba, Bolivia. This is an ongoing commitment of medication, to be resupplied as needed.

Treatment Grant (Ongoing)

In 2020, a treatment grant was made to ASLEK Epilepsy Foundation. This ongoing grant provides levetiracetam for clients of the foundation in Lubumbashi. A separate monetary grant was also made for ASLEK to locally purchase anti-epileptic drugs for clients experiencing hardships during the COVID-19 pandemic.

Treatment Grant (Ongoing)

In 2020, a treatment grant was made to Hopital Provincial General de Reference de Bukavu in east-central DRC. This ongoing grant provides levetiracetam and Subvenite® (starter kits and maintenance doses) for patients of the hospital’s new neuro-psychiatric department.

Training Grant (Completed)

In 2017, a training grant was provided to the Global Organization of Health Education (GOHE) for the purchase of technical materials to be used in training EEG technicians at Mekelle University in Ethiopia.

Treatment Grant (Ongoing)

In 2019, a treatment grant was provided to Grenada General Hospital in St. George’s. This grant provides Subvenite® (lamotrigine USP) anti-seizure medication.

Treatment Grant (Ongoing)

In 2020, a treatment grant was made to Massachusetts General Hospital, Global Neurology Research Group. This grant provides Roweepra® (levetiracetam USP) for epilepsy patients treated at Ignace Deen Hospital in the capital city of Conakry.

Treatment Grant (Ongoing)

In 2017, a treatment grant was provided to Children’s Hope, a US-based nonprofit operating a medical/dental clinic in Jacmel. This grant provides Roweepra® (levetiracetam USP) for epilepsy patients being treated through the clinic. This is an ongoing commitment of medication, to be resupplied as needed.

Treatment Grant (Ongoing)

In 2018 a treatment grant of Roweepra® (levetiracetam USP) anti-seizure medication was provided to Clinique d’Epilepsie de Port-au-Prince (CLIDEP) to augment medications available locally for treating patients with epilepsy. This is an ongoing commitment of medication.

Treatment Grant (Ongoing)

In 2018, a treatment grant was provided to Concerned Haitian Americans of Illinois (CHAI), a US-based nonprofit operating a medical clinic in a rural area near Cap-Haitien. This grant provides Roweepra® (levetiracetam USP) for epilepsy patients being treated through the clinic and students from CHAI’s two schools. This is an ongoing commitment of medication, to be resupplied as needed.

Diagnosis Grant (Completed)

In 2018, the ROW Foundation made a grant to Emmanuel Hospital Association for the purchase of two 32-channel mobile EEG units. The grant was fully funded by a generous donor family with personal ties to both epilepsy and India. The equipment placed at Champa Hospital in Chhattisgarh state and Duncan Hospital in Bihar state will serve poor and marginalized patients in these regions in central and northern India. (Duncan Hospital also serves patients from neighboring Nepal.)

Diagnosis Grant (Completed)

In 2018, the ROW Foundation granted funds to Santokba Durlabhji Memorial Hospital for the purchase of a portable 32-channel video EEG workstation in Jaipur, India. This EEG will be used in the pediatric ICU for diagnosis and monitoring of epilepsy for children in the greater Jaipur area.

Diagnosis Grant (Completed)

In 2016, mobile EEG equipment was provided to AIC Kijabe Hospital, a rural hospital in the Great Rift Valley of Kenya that had no EEG equipment, and no resident neurologists to read EEG studies. Through a grant to the Christian Medical and Dental Associations (CMDA), the equipment was placed, hospital staff were trained, and a mechanism for transmitting the EEG studies to volunteer neurologists in the United States was established. This allows volunteer neurologists to make diagnoses based on the EEG study data and to communicate with the health care providers at the hospital in Kenya who then provide treatment. Leveraged partnerships also resulted in a duplicate project at Tenwek Hospital.

Treatment Grant (Completed)

In 2018, the ROW Foundation provided a treatment grant of Roweepra® (levetiracetam USP) anti-seizure medication to the Kenya Association for the Welfare of People with Epilepsy.

Treatment Grant (Ongoing)

In 2020, a treatment grant was made to the Foundation for People with Epilepsy (FPE). This ongoing grant provides levetiracetam for clients assisted by FPE in Kilifi County, and also the Kiserem Epilepsy Foundation in Kiambu County, outside Nairobi.

Treatment Grant (Ongoing)

In 2020, a treatment grant was made to Save Haven Community Services. This grant provides Roweepra® (levetiracetam USP) for epilepsy patients treated through the organization’s outreach efforts in three of Liberia’s most populous counties.

Treatment Grant (Ongoing)

In 2019, a treatment grant was made to Loma Linda University Health for their epilepsy programs in Malawi. This grant provides Roweepra® (levetiracetam USP) for epilepsy patients treated at hospitals in Blantyre and Makwasa. This is an ongoing commitment of medication.

Training Grant (Completed)

In 2018, a grant was provided to the Global Organization for Health Education (GOHE) for trainers attending the first annual African Neurophysiology Annual Conference in Lagos. This event offers training for neurodiagnostic professionals from across Africa.

Training Grant(Completed)

In 2019, a training grant was made to the Yale University Global Mental Health Program. This funding supports The HAPPINESS Project, training primary care providers in Imo State to screen for and treat patients with mental disorders, substance abuse disorders and epilepsy. This is ROW Foundation’s first grant with a focus on psychiatry.

Treatment Grant (Ongoing)

In 2019, a treatment grant was made to the West Atlantic Brain and Stroke Foundation. This grant provides Roweepra (levetiracetam USP) for epilepsy patients treated through monthly clinics held at Regions Stroke and Neuroscience Hospital in Owerri. In 2020, the grant was expanded to include an ongoing supply of Subvenite® (lamotrigine USP).

Diagnosis Grant (Complete)

In 2018, a diagnosis grant in the form of a 32-channel video EEG workstation was given to the Georgian League Against Epilepsy, to be placed at the Institute for Neurology and Neuropsychology in Tbilisi. The new EEG workstation will allow the institute to diagnose under-resourced individuals with hard-to-treat epilepsies.

Treatment Grant (Ongoing)

In 2018, the ROW Foundation started providing anti-seizure medication to Loreto Clinic in the city of Makeni. Roweepra® (levetiracetam USP) anti-seizure medication augments locally available medication for treating patients with epilepsy. This medication grant is only possible through ROW’s partnership with the Healey International Relief Foundation.

Treatment Grant (Ongoing)

In 2018, the ROW Foundation provided Roweepra® (levetiracetam USP) for Medical Assistance Sierra Leone (MASL), a UK-based organization. In 2010, MASL and local partners established the first clinical epilepsy service in Sierra Leone. The supply is dispensed by Epilepsy Association Sierra Leone and will be replenished as needed.

Shipment of this grant was made possible by the Healey International Relief Foundation. 

In 2019, the grant was expanded to include an ongoing supply of Subvenite® (lamotrigine USP) anti-seizure medication.

Training Grant (Completed)

In 2019, ROW made a training grant to Medical Assistance Sierra Leone. The grant provides funding for the nation’s sole pediatric neurologist to attend an EEG training course in Cambridge, UK.

Diagnosis Grant (Completed)

In 2020, a diagnosis grant was made to TeleEEG for installation of their telemedicine services at Nyala Teaching Hospital in Nyala, Sudan. This will provide EEG services to patients from the local Darfur region, as well as the neighboring countries of Chad, Central African Republic and South Sudan.

Treatment Grant (Ongoing)

In 2019, the ROW Foundation granted 100 cases of RoweepraXR® (levetiracetam, extended-release tablets) for use at hospitals throughout northwest Syria. ROW became aware of this need through the Syrian American Medical Society (SAMS). Shipment of this grant was made possible by ROW partner Direct Relief.

Training Grant (Ongoing)

In 2019, a treatment grant was made to Provision Charitable Foundation. This grant of Subvenite® (lamotrigine USP) will supplement the locally-available supply of lamotrigine and benefit pregnant women treated by the Mahenge Epilepsy Clinic. This is an ongoing commitment of medication.

Treatment Grants (Completed)

In 2017, a grant was provided to Guiding Light Orphans (GLO) in Uganda to assist with the purchase of locally-available anti-seizure medications, and to support operation of their mobile epilepsy clinics. In 2019, GLO was named the recipient of the first Amanda Award, an annual award presented by ROW to an organization that achieves meaningful results in addressing untreated epilepsy. GLO received a $2500 grant to be used for the purchase of anti-epileptic drugs for their monthly epilepsy clinics.

Treatment Grant (Ongoing)

In 2017, a treatment grant was provided to CURE Children’s Hospital of Uganda, located in Mbale. This grant provides Roweepra (levetiracetam USP) to augment the locally available medications available for treating patients with epilepsy. This is an ongoing commitment of medication, to be resupplied every six months.

Other Grant (Completed)

ROW selected the Purple Bench Initiative as winner of the 2020 Amanda Award. The organization received a $2500 grant to further its mission through programs that create epilepsy awareness in the community and provide support to people living with epilepsy and their care takers.

Treatment Grant (Completed)

In 2016, a grant was provided to Epilepsy Health Management (EHM) to assist with modifications to a local epilepsy clinic in northern Illinois that will allow epilepsy patients with mobility issues – often as a result of traumatic brain injury – access services more easily.

Treatment Grant (Ongoing)

Since 2017, treatment grants have been made to two Epilepsy Foundation/Epilepsy Alliance chapters in the United States: Epilepsy Foundation of North/Central Illinois and Epilepsy Alliance North Carolina. The grants consist of Roweepra® (levetiracetam USP) and are used to provide care for epilepsy patients temporarily unable to access care. ROW Foundation is open to providing similar treatment grants to Epilepsy Foundation/Epilepsy Alliance chapters operating treatment clinics and serving under-resourced populations.

Treatment Grant (Completed)

In October 2017 ROW partnered with the Epilepsy Foundation of Greater Chicago and Dr. Rebecca Garcia Sosa of Lurie Children’s Hospital in Chicago to deliver a medication humanitarian aid shipment to Hospital Pediátrico Universitario (HOPU) in San Juan , Puerto Rico in the aftermath of Hurricane Maria. HOPU had been designated as a central hub for the receipt of medication humanitarian relief, and Dr. Janice Rodriguez Hernandez, Child Neurology Chief Resident, Fundación Hospital Pediátrico, was responsible for coordinating the distribution of the medication to where it was most needed until commercial pharmaceutical distribution could be restored.

Treatment Grant (Completed)

In 2018, the ROW Foundation made grants of Roweepra® (levetiracetam USP) to three organizations that provide medical relief in the U.S. and around the world. These partners have expanded our reach to dozens of under-resourced countries. In 2020, two of these organizations also received Subvenite® (lamotrigine USP) starter kits and maintenance doses.

Treatment Grant (Completed)

Since 2018, the ROW Foundation has provided emergency humanitarian aid shipments of Roweepra® (levetiracetam USP) to Cuatro por Venezuela. This medication has been distributed by the Venezuelan League Against Epilepsy (LIVECE) in Caracas, and by affiliated physicians throughout the country. To date, over 16,000 bottles of Roweepra® have been shipped.

Training Grant (Ongoing)

Through donor funding, ROW has made a training grant to Boston Children’s Hospital (BCH). The grant funds training of a local community health worker (CHW) cohort to reach out to families with children affected by epilepsy in an under-resourced compound on the edge of Lusaka. The CHWs will provide education on how to take medication, seizure precautions and seizure first aid. This program will also open dialogue with community leaders around epilepsy, helping reduce the harmful stigma and improve access to care.

Treatment Grant (Ongoing)

In 2019, a treatment grant was provided to University Teaching Hospital (UTH) Children’s Hospital. This is an ongoing commitment to provide Roweepra® (levetiracetam USP) to the pediatric hospital in Lusaka.

Treatment Grant (Ongoing)

In 2020, a treatment grant was provided to the Epilepsy Association of Zambia. This is an ongoing commitment to provide Roweepra® (levetiracetam USP) to support the association’s epilepsy clinic.

Training Grant (Completed)

In 2019, ROW made a training grant to the Global Organization for Health Education (GOHE).  GOHE is providing clinical training and evaluation for two neurodiagnostic technicians at Epilepsy Support Foundation Zimbabwe, located in Harare.

Make Your Mark

Your charitable contributions allow you to make your mark on the world!

Donate
shares